PTPTC Therapeutics PTCT · NASDAQ
$60.59 -3.89% (-$2.45)
- Market cap
- $5.26B
- Enterprise value
- $4.91B
- P/E
- -
- Forward P/E
- 37.1x
- PEG
- -
- P/S
- 5.2x
- P/FCF
- -
- EV/EBITDA
- 28.3x
- ROIC
- 2.6%
- Gross margin
- 82.1%
- Net margin
- -3.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -2.0x
- Beta
- 0.55
- Free float
- 88.3%
About the company
PTC Therapeutics, Inc. is an American biotechnology company that specializes in the development and commercialization of drugs for genetic and rare diseases. Founded in 1998, the company focuses on molecular therapies and innovative approaches to treating conditions that lack sufficient treatment options. PTC Therapeutics is dedicated to researching and developing drugs that target the genetic mechanisms of diseases, including conditions like Duchenne muscular dystrophy and other rare genetic disorders. The company has a global reach, with its drugs distributed in various countries.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Klein
Employees
991
Headquarters
Warren
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number